

THURSDAY
5th JUNE
2025

afpbn

ASSOCIATION FRANÇAISE
DE PSYCHIATRIE BIOLOGIQUE
NEUROPSYCHOPHARMACOLOGIE

afpbn
section
médecine
psychédélique

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

Organizing Committee :

Dr. Lucie Berkovitch
Dr. Hugo Bottemanne
Prof. Luc Mallet
Dr. Bruno Roméo

ICM - Institut du Cerveau

Hôpital Pitié-Salpêtrière
47 bd de l'Hôpital, 75013 Paris

Soutenu
par le



GOUVERNEMENT

Liberté
Egalité
Fraternité

MILDECA

Mission interministérielle
de lutte contre les drogues
et les conduites addictives

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

8:45 AM: Welcome

9:00 AM: Introduction - Bureau of the Psychedelic Medicine Section

09:15–10:00 AM: Pharmacology of psychedelics:
similarities and differences
Matthias Liechti, Basel University

10:00–10:45 AM: Psychedelic therapies - How do they seem to differ from
existing treatments in mental health?
David Erritzoe, Imperial College of London

10:45 –11:00 AM: Coffee Break

11:00 –11:45 AM: Mechanisms of psychedelics in the treatment of
alcohol dependence
Mickael Naassila, University of Picardy

11:45–12:30 AM: Are the neurobiological properties of psychedelics
predictive of therapeutic effects in addiction?
Christian Lüscher, University of Geneva

12:30–1:30 PM: Lunch Break

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

1:30 –2:00 PM: Processes and challenges in setting up a psilocybin study in France: example of the first French study (PAD)

Amandine Luquiens, CHU Nîmes

2:00–2:45 PM: Global brain effects of psychedelics and therapeutic implications

Katrin Preller, University Hospital for Psychiatry, Zurich

2:45–3:30 PM: LSD in the treatment of mood and anxiety disorders

Frederike Holze, Basel University

3:30–3:45 PM: Coffee Break

3:45 –4:30 PM: Psilocybin as a catalyst for psychotherapy?
Insights from the German EPIsoDE Trial

Lea Mertens, Central Institute of Mental Health,
University of Heidelberg

4:30–5:15 PM: Prospects on the use of psychedelic treatments as antidepressant therapy

Guy Goodwin, COMPASS Pathways, London

5:15–5:30 PM: Closing Remarks, Bureau of the Psychedelic Medicine Section

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

afpbn
section
médecine
psychédélique



SCANNEZ LE QR CODE POUR VOIR LA PAGE WEB DE LA SECTION

AGENCE PCO : COM'TO EVIDENCE

www.comtoevidence.com



CONTACT :

Mathias BRACCHETTI-GRANET

Email : contact@comtoevidence.com

Tél. : 33 (0)9 81 25 85 82